The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells

Journal of Immunology

Volumn 174, Issue 10, 2005, Pages 6308-6313

  Borsutzky, Stefan ^a   Kretschmer, Karsten ^a,d   Becker, Pablo D ^a   Mühlradt, Peter F ^b   Kirschning, Carsten J ^c   Weiss, Siegfried ^a   Guzmán, Carlos A ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b Wound Healing Research Group   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD19 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 2 RECEPTOR ALPHA; MACROPHAGE ACTIVATING FACTOR; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ACCESSORY CELL; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

EID: 18644372395     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.10.6308     Document Type: Article

References (60)

1. Matzinger, P. 2002. The danger model: a renewed sense of self. Science 296: 301-305.
2. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12: 991-1045.
3. Gallucci, S., and P. Matzinger. 2001. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13: 114-119.
4. Holmgren, J., N. Lycke, and C. Czerkinsky. 1993. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 11: 1179-1184.
5. Yamamoto, S., Y. Takeda, M. Yamamoto, H. Kurazono, K. Imaoka, K. Fujihashi, M. Noda, H. Kiyono, and J. R. McGhee. 1997. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 185: 1203-1210.
6. Roberts, M., A. Bacon, R. Rappuoli, M. Pizza, I. Cropley, G. Douce, G. Dougan, M. Marinaro, J. McGhee, and S, Chatfield. 1995. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity. PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect. Immun. 63: 2100-2108.
7. Rharbaoui, F., B. Drabner, S. Borsutzky, U. Winckler, M. Morr, B. Ensoli, P. F. Mühlradt, and C. A. Guzmán. 2002. The Mycoptosma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur. J. Immunol. 32: 2857-2865.
8. Borsutzky, S., V. Fiorelli, T. Ebensen, A. Tripiciano, F. Rharbaoui, A. Scoglio. C. Link. F. Nappi, M. Morr, S. Butto, et al. 2003. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur. J. Immunol 33: 1548-1556.
9. Takeuchi, O., A. Kaufmann, K. Grote, T. Kawai, K. Hoshino, M. Morr, P. F. Mühlradt, and S. Akira. 2000. Cutting edge: preferentially the R-stereoisomer of the mycoptasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway. J. Immunol. 164: 554-557.
10. Takeuchi, O., T. Kawai, P. F. Mühlradt, M. Morr, J. D. Radolf, A. Zychlinsky, K. Takeda, and S. Akira. 2001. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 13: 933-940.
11. Yamamoto, M., S. Sato, H. Hemmi, H. Sanjo, S. Uematsu, T. Kaisho, K. Hoshino, O. Takeuchi, M. Kobayashi, T. Fujita, K. Takeda, and S. Akira. 2002. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 420: 324-329.
12. Link, C., R. Gavioli, T. Ebensen, A. Canella, E. Reinhard, and C. A. Guzman. 2004. The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity. Eur. J. Immunol. 34: 899-907.
13. Caramalho, I., T. Lopes-Carvalho, D. Ostler, S. Zelenay, M. Haury, and J. Demengeot. 2003. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J. Exp. Med. 197: 403-411.
14. Engel, H., B. Bogen, U. Muller, J. Andersson, A. Rolink, and S. Weiss. 1998. Expression level of a transgenic λ2 chain results in isotype exclusion and commitment to B1 cells. Eur. J. Immunol. 28: 2289-2299.
15. Jumaa, H., B. Wollscheid, M. Mitterer, J. Wienands, M. Reth, and P. J. Nielsen. 1999. Abnormal development and function of B lymphocytes in mice deficient for the signaling adaptor protein SLP-65. Immunity 11: 547-554.
16. Flemming, A., T. Brummer, M. Reth, and H. Jumaa. 2003. The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion. Nat. Immunol. 4: 38-43.
17. Pelanda, R., U. Braun, E. Hobeika, M. C. Nussenzweig, and M. Reth. 2002. B cell progenitors are arrested in maturation but have intact VDJ recombination in the absence of Ig-α and Ig-β. J. Immunol. 169: 865-872.
18. Kretschmer, K., A. Jungebloud, J. Stopkowicz, B. Stoermann, R. Hoffmann, and S. Weiss. 2003. Antibody repertoire and gene expression profile: implications for different developmental and functional traits of splenic and peritoneal B-1 lymphocytes. J. Immunol. 171: 1192-1201.
19. Mühlradt, P. F., M. Kiess, H. Meyer, R. Süssmuth, and G. Jung. 1997. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J. Exp. Med. 185: 1951-1958.
20. Melchers, F., V. Braun, and C. Galanos. 1975. The lipoprotein of the outer membrane of Escherichia coli: a B-lymphocyte mitogen. J. Exp. Med. 142: 473-482.
21. Davis, K. L., and K. S. Wise. 2002. Site-specific proteolysis of the MALP-404 lipoprotein determines the release of a soluble selective lipoprotein-associated motif-containing fragment and alteration of the surface phenotype of Mycoplasma fermentans. Infect. Immun. 70: 1129-1135.
22. Yogev, D., G. F. Browning, and K. Wise. 2002. Genetic mechanisms of surface variation. In Molecular Biology and Pathogenesis of Mycoplasmas. R. Herrmann, ed. Kluwer Academic/Plenum, New York, Boston, Dordrecht. London, Moscow, p. 417-444.
23. Weigt, H., P. F. Mühlradt, A. Emmendorffer, N. Krug, and A. Braun. 2003. Synthetic mycoplasma-derived lipopeptide MALP-2 induces maturation and function of dendritic cells, Immunobiology 207: 223-233.
24. Snapper, C. M., F. R. Rosas, L. Jin, C. Wortham, M. R. Kehry, and J. J. Mond. 1995. Bacterial lipoproteins may substitute for cytokines in the humoral immune response to T cell-independent type 11 antigens. J. Immunol. 155: 5582-5589.
25. Lowenthal, J. W., R. H. Zubler, M. Nabholz, and H. R. MacDonald. 1985. Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes. Nature 315: 669-672.
26. Taniguchi, T., and Y. Minami. 1993. The IL-2/IL-2 receptor system: a current overview. Cell 73: 5-8.
27. Carter, R. H., and D. T. Fearon. 1992. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256: 105-107.
28. Sato, S., D. A. Steeber, and T. F. Tedder. 1995. The CD 19 signal transduction molecule is a response regulator of B-lymphocyte differentiation. Proc. Natl. Acad. Sci. USA 92: 11558-11562.
29. Kurt-Jones, E. A., D. Liano, K. A. HayGlass, B. Benacerraf, M. S. Sy, and A. K. Abbas. 1988. The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice. J. Immunol. 140: 3773-3778.
30. Morris, S. C., A. Lees, and F. D. Finkelman. 1994. In vivo activation of naive T cells by antigen-presenting B cells. J. Immunol 152: 3777-3785.
31. + T cell priming in vivo. J. Immunol. 162: 5695-5703.
32. Baumgarth, N. 2000. A two-phase model of B-cell activation, Immunol. Rev. 176: 171-180.
33. Boes, M., C. Esau, M. B. Fischer, T. Schmidt, M. Carroll, and J. Chen. 1998. Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. J. Immunol. 160: 4776-4787.
34. Ehrenstein, M. R., T. L. O'Keefe, S. L. Davies, and M. S. Neuberger. 1998. Targeted gene disruption reveals a role for natural secretory IgM in the maturation of the primary immune response. Proc. Natl. Acad. Sci. USA 95: 10089-10093.
35. Henry, C., and N. K. Jerne. 1968. Competition of 19S and 7S antigen receptors in the regulation of the primary immune response. J. Exp. Med. 128: 133-152.
36. Heyman, B., G, Andrighetto, and H. Wigzell. 1982. Antigen-dependent IgM-mediated enhancement of the sheep erythrocyte response in mice: evidence for induction of B cells with specificities other than that of the injected antibodies. J. Exp. Med. 155: 994-1009.
37. Lehner, P., P. Hutchings, P. M. Lydyard, and A. Cooke. 1983. II. IgM-mediated enhancement: dependency on antigen dose, T-cell requirement and lack of evidence for an idiotype-related mechanism. Immunology 50: 503-509.
38. Cooper, N. R. 1985. The classical complement pathway: activation and regulation of the first complement component. Adv. Immunol 37: 151-216.
39. Papamichail, M., C. Gutierrez, P. Embling, P. Johnson, E. J. Holborow, and M. B. Pepys. 1975. Complement dependence of localisation of aggregated IgG in germinal centres. Scand. J. Immunol. 4: 343-347.
40. Chen L. L., A. M. Frank, J. C. Adams, and R. M. Steinman. 1978. Distribution of horseradish peroxidase (HRP)-anti-HRP immune complexes in mouse spleen with special reference to follicular dendritic cells. J. Cell Biol. 79: 184-189.
41. Enriquez-Rincon, F., and G. G. Klaus. 1984. Follicular trapping of hapten-erythrocyte-antibody complexes in mouse spleen. Immunology 52: 107-116.
42. Dempsey, P. W., M. E. Allison, S. Akkaraju, C. C. Goodnow, and D. T. Fearon. 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271: 348-350.
43. Rickert, R. C., K. Rajewsky. and J. Roes. 1995. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 376: 352-355.
44. Croix, D. A., J. M. Ahearn, A. M. Rosengard, S. Han, G. Kelsoe, M. Ma, and M. C. Carroll. 1996. Antibody response to a T-dependent antigen requires B cell expression of complement receptors. J. Exp. Med. 183: 1857-1864.
45. Aheam, J. M., M. B. Fischer, D. Croix, S. Goerg, M. Ma, J. Xia, X. Zhou, R. G. Howard, T. L. Rothstein, and M. C. Carroll. 1996. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 4: 251-262.
46. Shibuya, A., N. Sakamoto, Y. Shimizu, K. Shibuya, M. Osawa, T. Hiroyama, H. J. Eyre, G, R. Sutherland, Y. Endo, T. Fujita, et al. 2000. Fc α/β receptor mediates endocytosis of IgM-coated microbes. Nat. Immunol, 1: 441-446.
47. Brandtzaeg, P., and H. Prydz. 1984. Direct evidence for an integrated function of J chain and secretory component in epithelial transport of immunoglobulins. Nature 311: 71-73.
48. Alexopoulou, L., V. Thomas, M. Schnare, Y. Lobet, J. Anguita, R. T. Schoen, R. Medzhitov, E. Fikrig, and R. A. Flavell, 2002. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat. Med. 8: 878-884.
49. Takeuchi. O., S. Sato, T. Horiuchi, K. Hoshino, K. Takeda, Z. Dong, R. L. Modlin, and S. Akira. 2002. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 169: 10-14.
50. Massari, P., P. Henneke, Y. Ho, E. Latz, D. T. Golenbock, and L. M. Wetzler. 2002. Cutting edge: Immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent. J. Immunol. 168: 1533-1537.
51. Bishop, G. A., Y. Hsing, B. S. Hostager, S. V. Jalukar, L. M. Ramirez, and M. A. Tomai. 2000. Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J. Immunol, 165: 5552-5557.
52. Bishop, G. A., L. M. Ramirez, M. Baccam, L. K. Busch, L. K. Pederson, and M. A. Tomai. 2001. The immune response modifier resiquimod mimics CD40-induced B cell activation. Cell. Immunol. 208: 9-17.
53. Tomai, M. A., L. M. Imbertson, T. L. Stanczak, L. T. Tygrett, and T. J. Waldschmidt. 2000. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol. 203: 55-65.
54. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop. R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
55. Chen, W., Y. Yu, C. Shao, M. Zhang, W. Wang, L. Zhang, and X. Cao. 2001. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody. Immunol. Lett. 77: 17-23.
56. Erdile, L. F., and B. Guy. 1997. OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant. Vaccine 15: 988-996.
57. Schlecht, S., K. H. Wiesmuller, G. Jung, and W. G. Bessler. 1989. Enhancement of protection against Salmonella infection in mice mediated by a synthetic lipopeptide analogue of bacterial lipoprotein in S. typhimurium vaccines. Zentralbl Bakteriol. 271: 493-500.
58. Vasilakos, J. P., R. M. Smith, S. J. Gibson, J. M. Lindh, L. K. Pederson, M. J. Reiter, M. H. Smith, and M. A. Tomai. 2000. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell. Immunol. 204: 64-74.
59. Fusco, P. C., F. Michon, M. Laude-Sharp, C. A. Minetti, C. H. Huang. I. Heron, and M. S. Blake. 1998. Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine. Vaccine 16: 1842-1849.
60. Moldoveanu, Z., L. Love-Homan, W. Q. Huang, and A. M. Krieg. 1998. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16: 1216-1224.